Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
AdvaMed Works with Evaluate to Provide AdvaMed Members Strategic Insights via EvaluateMedTech®
The annual EvaluateMedTech World Preview report launched at AdvaMed 2015 in San Diego, CA showcasing the 2020 sector outlook.
LONDON, UK and WASHINGTON, DC (October 28, 2015) – Kenneth Mendez, chief administrative officer of the Advanced Medical Technology Association (AdvaMed) and Alexander Karle, CEO of life science market intelligence firm Evaluate Ltd today announced a collaboration to arrange for preferred medtech market intelligence services, which features insightful market intelligence via exclusive reports plus AdvaMed member discounts for the EvaluateMedTech service.
“EvaluateMedTech® offers value to AdvaMed members through its high-quality, timely coverage of the global medtech sector. It saves time spent on complex data aggregation and analyses which can inform critical business decisions more rapidly,” said Karle.
The EvaluateMedTech World Preview report provides a comprehensive annual industry analysis including segment sales and forecasts of the sector to 2020, as well as regulatory approvals, M&A, IPOs, venture financing and R&D spend of top companies. This complimentary report was launched at the AdvaMed conference, this year in San Diego. “We are honored to support AdvaMed member companies through the preferred provider program,” said Karle. “We are committed to deliver AdvaMed members the highest quality, and most trusted medtech commercial intelligence available. Our focus is on our clients; their regular input and feedback drive our product innovation.”
Key Features of EvaluateMedTech® include:
- Consensus Sales Forecasts to 2020
- Company Segment Sales, Financials and Employee Numbers
- M&A, Venture Financing and IPOs
- Regulatory Approvals: Devices@FDA, CE Marks and PMDA (Japan)
- R&D Spend and Clinical Trials
- Company Device Portfolios: Marketed and R&D products
- Epidemiology and Procedures Data
- News, Commentary, Analysis and Special Reports
- Merge Company and Peer Group Analyzer Tools
- Workflow Support Tools
For more information please visit: www.evaluategroup.com/AdvaMed
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems.
For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage, @evaluateJP.
Back to Press Releases